HFA Hep C Patient Support Programme
It is unfortunate that some patients in the UK are unable to get treatment because either their liver disease is not sufficiently advanced or because treatment is considered too expensive. Costs of treatment for sofosbuvir, daclatasvir and the combinations of sofosbuvir+velpatasvir range from £8,000 to £13,000 per 28 tablet pack. Pretty expensive and prohibitive for the NHS.
The HFA Patient Support Programme puts patients in direct contact with the Manufacturer of generic versions of these expensive drugs at a fraction of the price, which are approved in the country of manufacture.
Our Manufacturing and Regulatory team have visited the facilities of Beacon Pharmaceuticals in Bangladesh. We have reviewed their technical documentation and ensured their adherence to Good Manufacturing Practice (GMP) for the manufacture of hepatitis C products, for which they are approved by the Directorate General of Drug Administration (DGDA) in Bangladesh. We have also met with the head of the DGDA in Dhaka outlining our plans.
Do not trust any on-line pharmacy, especially for critical life saving drugs.
The HFA Patient Support Programme is run by an established pharmaceutical company already supplying the NHS with approved prescription products.
Our Patient Support Programme is our way of providing a unique added value service to patients in the UK who are unable to get treatment because either their liver disease is not sufficiently advanced or because treatment is considered too expensive.
Research shows that generic drugs are as effective as the original versions. However, there are also fake or poor quality drugs being sold.
The HFA Patient Support Programme uses reputable manufacturers of generic drugs.
The following products are presently available under the HFA Hep C Patient Support Programme. Click on the product name for further details:
Sofosvel (sofosbuvir 400mg + velpatasvir 100mg)
Sofosvel is the global first generic oral tablet for pan-genotypic Chronic Hepatitis C treatment. This combination (Sofosbuvir 400 mg + Valpatasvir 100 mg) drug has been approved by US FDA & European Commission for treatment of patients with all genotypic Chronic Hepatitis C virus infection. Sofosvel is used without cirrhosis or with compensated cirrhosis, and patients with advanced cirrhosis (Decompensated).
Therapeutic indications:
Sofosvel is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infections
- With or without cirrhosis or with compensated cirrhosis
- With decompensated cirrhosis for use in combination with Ribavirin
Product Features:
Product Name: Sofosvel
Generic Name: Sofosbuvir 400mg + Velpatasvir 100 mg
Formulation: Solid dosage form(Tablet)
Available pack size: 1×6's
Strengths: 400mg+ 100mg
Availability: By prescription, for personal use only and through the HFA Hep C Patient Support Programme
Sofosbuvir + Daclatasvir (Darvoni)
Product Description:
Sofosbuvir directly targets the Hepatitis C virus to stop it from making copies of itself in the liver. Sofosbuvir attaches itself to the genetic information, called RNA, to block the virus from multiplying. And Daclatasvir is a direct-acting antiviral agent (DAA) against the hepatitis C virus.
Product Features:
Product Name: Darvoni
Generic Name: Sofosbuvir 400 mg and Daclatasvir 60 mg
Formulation: Tablet
Available pack size: 1×6's
Strengths: Sofosbuvir 400 mg and Daclatasvir 60 mg
Availability: By prescription, for personal use only and through the HFA Hep C Patient Support Programme
Ribavirin (Copeg)
Product Description:
Ribavirin is an anti-viral drug indicated for severe RSV infection (individually), Hepatitis C infection (used in conjunction with Peginterferon) and other viral infections. Ribavirin is a prodrug, which when metabolized resembles purine RNA nucleotides. In this form it interferes with RNA metabolism required for viral replication. How it exactly affects viral replication is unknown; many mechanisms have been proposed for this but none of these has been proven to date. Multiple mechanisms may be responsible for its actions.
Product Features:
Product Name: Copeg
Generic Name: Ribavirin
Formulation: Tablet
Available pack size: 20's
Strengths: 200 mg
Availability: By prescription, for personal use only and through the HFA Hep C Patient Support Programme
Soforal-LP (Sofosbuvir 400 mg/Ledipasvir 90 mg) tablet
Soforal-LP is the generic version of wondering drug Harvoni tablet for Hepatitis C genotype 1,4,5 & 6. In clinical studies, 96-99% of patients with hepatitis c genotype 1 were cured who has a story of no prior treatment.
Therapeutic Indications:
Soforal-LP is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection.
Product Features:
Product Name: Soforal-LP
Generic Name: Sofosbuvir 400 mg + Velpatasvir 90
Available pack size: 1x6's
Strengths: 400 mg + 90 mg
Availability: By prescription, for personal use only and through the HFA Hep C patient support program.
Yes it is legal to import these drugs into the UK for personal use.
The HFA Patient Support Programme will facilitate this process.
12 weeks treatment is normally considered for personal use.
It is important to realise that these generic drugs are not yet approved by the UK regulatory authorities and cannot be promoted to healthcare professions within the NHS.
They are however approved in certain countries outside the UK.
Whilst it is not illegal for a patient to directly import these generic drugs for personal use, patients considering importing should be aware of this.
Whilst these generic drugs have not yet gone through the exhaustive UK regulatory approval process, the HFA Patient Support Programme ensures each batch from which the pack you will receive has been tested and a Certificate of Analysis is in our possession which confirms the product meets its specification - i.e. It contains what it say it contains
The European Association for the Study of the Liver (EASL) started as a small group of 70 hepatologists from 15 European countries who came together to share best medical practice in April 1966. Over the last 50 years the EASL has evolved into a major European Association with international influence dedicated to the liver and liver disease.
EASL now boasts over 4,000 members globally and provides an annual platform, The International Liver Congress, for 11,000 liver experts to meet and discuss latest scientific research. EASL has given rise to many international clinical trials and research collaborations to the benefit of patients all over the world.
HFA Healthcare will be attending the International Liver Congress 2017 being organized by EASL in Amsterdam, Netherlands.
